Zobrazeno 1 - 10
of 87
pro vyhledávání: '"immune check inhibitor (ICI)"'
Autor:
Monica Mariniello, Giulia Arrivi, Laura Tufano, Antonio Lauletta, Mirella Moro, Giacomo Tini, Matteo Garibaldi, Raffaele Giusti, Federica Mazzuca
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Immunotherapy is increasingly used in advanced non-small-cell lung cancer (NSCLC), offering a significant anti-tumor response, as well as causing rising immune-related adverse effects. The incidence of immune checkpoint inhibitor-induced myocarditis
Externí odkaz:
https://doaj.org/article/d6ae407a595a40d6b255b4a9b4173d48
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe use of immune checkpoint inhibitors (ICIs) has become the standard of care for non-small cell lung cancer. The purpose of this study was to systematically review the literature to determine whether the occurrence of immune-related adver
Externí odkaz:
https://doaj.org/article/0b2ab6e0430b467caf3ae30db2a85e05
Autor:
Melchior Chabannes, Ziriab Lisri, Stéphane Lang, Jean Seibel, Guillaume Eberst, Didier Ducloux, Céline Pursun, Marie Agnes Dragon Durey, Marie-Alexandra Alyanakia, Sophie Felix, Thomas Crepin
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Immune checkpoint inhibitors (ICIs) dramatically improve the prognosis of many malignancies but at the cost of numerous side effects, which may limit their benefits. Acute kidney injury associated with immune checkpoint inhibitors most frequently are
Externí odkaz:
https://doaj.org/article/53a65155426c469aa694c766225dbd99
Autor:
Dina Poplausky, Jade N. Young, Brandon R. Block, Yeriel Estrada, Giselle K. Singer, Vicky Wong, Patricia Cabral, Yamato Suemitsu, Randie H. Kim, Philip Friedlander, Nicholas Gulati
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
While typically low-risk, cutaneous squamous cell carcinoma (cSCC) can infrequently progress to metastatic disease with in-transit lesions, localized to the dermis or subcutaneous tissue between the primary tumor and draining regional lymph nodes. Th
Externí odkaz:
https://doaj.org/article/0fed82361a9c47cbb9e8720c45f331b8
Autor:
Isabella Sala, Eleonora Pagan, Laura Pala, Chiara Oriecuia, Marco Musca, Claudia Specchia, Tommaso De Pas, Javier Cortes, Giuseppe Giaccone, Michael Postow, Richard D. Gelber, Vincenzo Bagnardi, Fabio Conforti
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThere is debate on which are the best surrogate endpoint and metric to capture treatment effect on overall survival (OS) in RCTs testing immune-checkpoint inhibitors (ICIs).MethodsWe systematically searched for RCTs testing ICIs in patien
Externí odkaz:
https://doaj.org/article/41a1befd79f048e8a9b532a6878b8f02
Autor:
Shalin Abraham, Adel Samson
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
In the last five years, the advent of combination immune checkpoint inhibitor atezolizumab and anti-angiogenic agent bevacizumab has transformed treatment of unresectable hepatocellular carcinoma. As patient outcomes improve, healthcare professionals
Externí odkaz:
https://doaj.org/article/6da110124b93492ba01db2215a448f93
Autor:
Yuxiang Wang, Athar Khalil, Amina Kamar, Mengyan Du, Trang Dinh, Christopher McFarland, Zhenghe Wang
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by reinvigorating antitumor immune responses, but their efficacy remains limited in most patients. To address this challenge and optimize Immune check inhibitor treatment, u
Externí odkaz:
https://doaj.org/article/20c4cc8cf10e4da79882b7dc91730668
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/d15c03e29023454e9f7e93eb187d1781
Autor:
Luciano Mutti, Steven G. Gray
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/aa518c0a2569414bb99364c5efb36c98
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Among all malignant tumors, lung cancer has the highest mortality and morbidity rates. The non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the most common histological subtypes. Although there are a number of internationally
Externí odkaz:
https://doaj.org/article/637eb4155cf842d2ac6e82aaa4b5e9cc